Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/ofid/ofab013 http://scihub22266oqcxt.onion/10.1093/ofid/ofab013 33628858!7890594!33628858     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Open+Forum+Infect+Dis 2021 ; 8 (2): ofab013 Nephropedia Template TP {{tp|p=33628858|t=2021. Is There Still a Place for Tocilizumab in Coronavirus Disease 2019?|pdf=|usr=}}{{33628858}} gab.com Text Is There Still a Place for Tocilizumab in Coronavirus Disease 2019 JO: Open Forum Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33628858 #FOAvip In this article, we sought to summarize the available evidence of tocilizumab as a treatment for coronavirus disease 2019. Recent tocilizumab randomized trials have not shown clear evidence of efficacy, especially on mortality, in contrast to observational studies. These clinical trials focus on a heterogeneous population of patients (clinical severity and inflammatory stage), and this is possibly one of the reasons that explain heterogeneity of results. However, these same trials have shown some evidence that tocilizumab may reduce intensive care unit admissions and/or mechanical ventilation incidence, which are huge challenges in the severe acute respiratory syndrome coronavirus 2 pandemic. Future clinical trials with primary endpoint built on this assumption are needed (1) to confirm whether tocilizumab reduces mechanical ventilation requirement and (2) to describe the right patient population and optimal timing for tocilizumab administration. Finding the optimal timing for tocilizumab administration and the group of patients who are susceptible to having the greatest benefit are probably the main challenge. Twit Text FOAVip Is There Still a Place for Tocilizumab in Coronavirus Disease 2019 ????Open Forum Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33628858 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33628858 #FOAvip English Wikipedia <ref>{{Cite pmid|33628858}}</ref> Is There Still a Place for Tocilizumab in Coronavirus Disease 2019? #MMPMID33628858 Klopfenstein T; Conrozier T; Kadiane-Oussou NJ; Gendrin V; Zayet S Open Forum Infect Dis 2021[Feb]; 8 (2): ofab013 PMID33628858show ga In this article, we sought to summarize the available evidence of tocilizumab as a treatment for coronavirus disease 2019. Recent tocilizumab randomized trials have not shown clear evidence of efficacy, especially on mortality, in contrast to observational studies. These clinical trials focus on a heterogeneous population of patients (clinical severity and inflammatory stage), and this is possibly one of the reasons that explain heterogeneity of results. However, these same trials have shown some evidence that tocilizumab may reduce intensive care unit admissions and/or mechanical ventilation incidence, which are huge challenges in the severe acute respiratory syndrome coronavirus 2 pandemic. Future clinical trials with primary endpoint built on this assumption are needed (1) to confirm whether tocilizumab reduces mechanical ventilation requirement and (2) to describe the right patient population and optimal timing for tocilizumab administration. Finding the optimal timing for tocilizumab administration and the group of patients who are susceptible to having the greatest benefit are probably the main challenge. äIs There Still a Place for Tocilizumab in Coronavirus Disease 2019?(epmc).pdf DeepDyve Pubget Overpricing